Cushing's Disease Preceded by Generalized Glucocorticoid Resistance: Clinical Consequences of a Novel, Dominant-negative Glucocorticoid Receptor Mutation
Overview
Authors
Affiliations
Generalized glucocorticoid resistance is associated with chronic hyperactivation of the hypothalamic-pituitary-adrenal axis, compensating for impaired glucocorticoid receptor function. We report a unique patient with sporadic generalized glucocorticoid resistance who, at age 33, presented with infertility and hypertension and, at 38, developed pituitary Cushing's disease. Leukocyte-binding studies revealed normal affinity of the glucocorticoid receptor but a reduction of binding sites by 50%. [3H]thymidine incorporation by this patient's lymphocytes was not suppressible by dexamethasone. He had a novel heterozygous missense mutation in the glucocorticoid receptor gene (isoleucine 559 to asparagine 559). The mutant receptor exhibited a strong dominant-negative effect on the ability of the wild-type receptor to induce gene transcription in vitro. The mutation was present in all of the patient's cultured lymphoblasts and fibroblasts as well as in 50% of his sperm, as demonstrated by single-cell polymerase chain reaction; it was not present in his parents and seven siblings. This novel mutation was thus both de novo and present in the germ line. Immunohistochemical staining of this patient's pituitary corticotropinoma revealed accumulation of p53 protein, indicating the presence of a putative somatic oncogenic mutation in the p53 gene in the tumor cells. Investigation of the lymphoblast and skin fibroblast cultures for p53 abnormalities did not show any aberration. Thus, a novel de novo germ line mutation of the glucocorticoid receptor with strong dominant-negative activity caused severe sporadic generalized glucocorticoid resistance, which preceded corticotroph adenoma formation. The latter probably was due to the combined effects of chronic corticotroph hyperstimulation, decreased glucocorticoid negative feedback, and at least one subsequent somatic defect in the control of the cell cycle.
[Primary Generalized Glucocorticoid Resistance: a case report].
Larina I, Makazan N, Ivashchenko K, Platonova N, Orlova E, Kareva M Probl Endokrinol (Mosk). 2024; 70(1):30-37.
PMID: 38433539 PMC: 10926243. DOI: 10.14341/probl13321.
Hypercortisolaemia without clinical stigmata of Cushing syndrome.
Krishna S, Morton A BMJ Case Rep. 2024; 17(1).
PMID: 38286578 PMC: 10826528. DOI: 10.1136/bcr-2023-258286.
Advances in Molecular Pathophysiology and Targeted Therapy for Cushing's Disease.
Takayasu S, Kageyama K, Daimon M Cancers (Basel). 2023; 15(2).
PMID: 36672445 PMC: 9857185. DOI: 10.3390/cancers15020496.
Role of glucocorticoid receptor mutations in hypertension and adrenal gland hyperplasia.
Verouti S, Hummler E, Vanderriele P Pflugers Arch. 2022; 474(8):829-840.
PMID: 35732960 PMC: 9217122. DOI: 10.1007/s00424-022-02715-6.
Primary Generalized Glucocorticoid Resistance and Hypersensitivity Syndromes: A 2021 Update.
Nicolaides N, Charmandari E Int J Mol Sci. 2021; 22(19).
PMID: 34639183 PMC: 8509180. DOI: 10.3390/ijms221910839.